JP2008531470A5 - - Google Patents

Download PDF

Info

Publication number
JP2008531470A5
JP2008531470A5 JP2007547106A JP2007547106A JP2008531470A5 JP 2008531470 A5 JP2008531470 A5 JP 2008531470A5 JP 2007547106 A JP2007547106 A JP 2007547106A JP 2007547106 A JP2007547106 A JP 2007547106A JP 2008531470 A5 JP2008531470 A5 JP 2008531470A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
phenyl
benzyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007547106A
Other languages
English (en)
Japanese (ja)
Other versions
JP4966202B2 (ja
JP2008531470A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2005/001975 external-priority patent/WO2006066361A1/en
Publication of JP2008531470A publication Critical patent/JP2008531470A/ja
Publication of JP2008531470A5 publication Critical patent/JP2008531470A5/ja
Application granted granted Critical
Publication of JP4966202B2 publication Critical patent/JP4966202B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007547106A 2004-12-24 2005-12-23 治療または予防のための方法 Expired - Lifetime JP4966202B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2004907332 2004-12-24
AU2004907332A AU2004907332A0 (en) 2004-12-24 Method of Treatment or Prophylaxis
PCT/AU2005/001975 WO2006066361A1 (en) 2004-12-24 2005-12-23 Method of treatment or prophylaxis

Publications (3)

Publication Number Publication Date
JP2008531470A JP2008531470A (ja) 2008-08-14
JP2008531470A5 true JP2008531470A5 (https=) 2008-12-25
JP4966202B2 JP4966202B2 (ja) 2012-07-04

Family

ID=36601295

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007547106A Expired - Lifetime JP4966202B2 (ja) 2004-12-24 2005-12-23 治療または予防のための方法

Country Status (16)

Country Link
US (5) US7795275B2 (https=)
EP (3) EP2650010A1 (https=)
JP (1) JP4966202B2 (https=)
CN (3) CN102861019B (https=)
CY (1) CY1114424T1 (https=)
DK (1) DK1830869T3 (https=)
ES (1) ES2425567T3 (https=)
HR (1) HRP20130738T1 (https=)
ME (1) ME01597B (https=)
NZ (1) NZ555334A (https=)
PL (1) PL1830869T3 (https=)
PT (1) PT1830869E (https=)
RS (1) RS52927B (https=)
SI (1) SI1830869T1 (https=)
WO (1) WO2006066361A1 (https=)
ZA (3) ZA200704909B (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066361A1 (en) 2004-12-24 2006-06-29 The University Of Queensland Method of treatment or prophylaxis
CA2866540A1 (en) 2006-03-20 2007-09-27 Spinifex Pharmaceuticals Pty Ltd. Method of treatment or prophylaxis of inflammatory pain
CA2665476A1 (en) * 2006-10-05 2008-04-10 Cv Therapeutics, Inc. Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors
US20090105283A1 (en) * 2007-04-11 2009-04-23 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US20080255161A1 (en) * 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US7828840B2 (en) 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
US20100267752A1 (en) * 2008-10-15 2010-10-21 Gilead Palo Alto, Inc. 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
WO2010056230A1 (en) * 2008-10-15 2010-05-20 Cv Therapeutics, Inc. 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
NZ601383A (en) * 2010-01-19 2014-07-25 Spinifex Pharm Pty Ltd Methods and compositions for improved nerve conduction velocity
DE102010013075A1 (de) 2010-03-26 2011-09-29 B. Braun Melsungen Ag Antimikrobielle Wundauflage
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
AU2011281381B2 (en) * 2010-07-21 2015-07-16 Novartis Ag Salt and solvates of a tetrahydroisoquinoline derivative
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
PL2748166T3 (pl) 2011-08-23 2019-05-31 Asana Biosciences Llc Związki pirimido-pirydazynonowe oraz ich zastosowanie
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
ES2802251T3 (es) 2012-01-06 2021-01-18 Novartis Ag Compuestos heterocíclicos y métodos para su uso
ES2798289T3 (es) 2012-01-25 2020-12-10 Novartis Ag Compuestos heterocíclicos y métodos para su uso
PT2807171T (pt) 2012-01-25 2020-11-03 Novartis Ag Compostos heterocíclicos e métodos para a sua utilização
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
ES2883155T3 (es) 2013-07-08 2021-12-07 Novartis Ag Compuestos heterocíclicos y métodos para su uso
EP3051944B1 (en) 2013-09-30 2023-11-01 FMC Corporation Method of delivering an agriculturally active ingredient
ES2734060T3 (es) 2014-01-17 2019-12-04 Cardioxyl Pharmaceuticals Inc Donadores de nitroxilo de N-hidroximetanosulfonamida
HRP20210319T1 (hr) 2014-03-26 2021-04-30 Astex Therapeutics Ltd. Kombinacije inhibitora fgfr i inhibitora igf1r
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
RU2715236C2 (ru) 2014-03-26 2020-02-26 Астекс Терапьютикс Лтд Комбинации
UY36181A (es) 2014-06-24 2016-09-30 Fmc Corp Formulaciones de espumas y concentrados emulsionables
JP6667551B2 (ja) 2015-01-13 2020-03-18 ノバルティス アーゲー アンジオテンシンｉｉ２型拮抗薬としてのピロリジン誘導体
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
US10308628B2 (en) 2015-03-12 2019-06-04 Novartis Ag Heterocyclic compounds and methods for their use
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CN106478502B (zh) * 2015-08-29 2021-04-27 上海翰森生物医药科技有限公司 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用
EP3353164B1 (en) 2015-09-23 2021-11-03 Janssen Pharmaceutica, N.V. Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
US11155555B2 (en) 2015-09-23 2021-10-26 Janssen Pharmaceutica Nv Compounds
KR20180098320A (ko) 2015-12-23 2018-09-03 에프엠씨 코포레이션 고랑에서의 종자의 현장 처리
WO2018001997A1 (en) 2016-06-27 2018-01-04 Ratiopharm Gmbh Crystalline calcium salt of (s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid
JP2019514862A (ja) 2017-03-23 2019-06-06 ノバルティス アーゲー （ｓ）−２−（ジフェニルアセチル）−１，２，３，４−テトラヒドロ−６−メトキシ−５−（フェニルメトキシ）−３−イソキノリンカルボン酸ナトリウムの無水結晶形
CN118105392A (zh) 2017-04-28 2024-05-31 自由生物有限公司 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型
PT3620454T (pt) * 2017-06-09 2021-09-10 Shandong Danhong Pharmaceutical Co Ltd Derivado de ácido carboxílico como antagonista do recetor at2r
GB201710906D0 (en) * 2017-07-06 2017-08-23 Vicore Pharma Ab Compounds and methods for treating peripheral neuropathy
KR102865307B1 (ko) * 2018-02-23 2025-09-26 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 수용체 억제제, 이를 포함하는 약학적 조성물 및 그 용도
CN117645606A (zh) 2018-03-23 2024-03-05 北京泰德制药股份有限公司 受体抑制剂、包含其的药物组合物及其用途
WO2019238962A1 (en) * 2018-06-14 2019-12-19 University College Cork - National University Of Ireland, Cork Peptide for disease treatment
WO2020012266A1 (en) 2018-07-12 2020-01-16 Novartis Ag Biocatalytic synthesis of olodanrigan (ema401) from 3-(2-(benzyloxy)-3-methoxyphenyl)propenoic acid with phenylalanine ammonia lyase
PE20241304A1 (es) 2021-07-30 2024-06-24 Confo Therapeutics N V Compuestos para el tratamiento del dolor, en particular el dolor neuropatico, y/u otras enfermedades o trastornos que se asocian con at2r y/o senalizacion mediada por at2r
US12122750B2 (en) 2022-05-17 2024-10-22 Eli Lilly And Company AT2R antagonists and uses thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3531485A (en) * 1967-08-14 1970-09-29 American Home Prod Aryl-substituted diazabicycloalkanes
US3957795A (en) * 1974-01-28 1976-05-18 Delmar Chemicals Limited Novel cyclopentene and cyclopentane derivatives
US3975795A (en) 1975-01-20 1976-08-24 Union Carbide Corporation Product stuffing apparatus and method
US4812462A (en) * 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
US5091390A (en) 1990-09-20 1992-02-25 E. I. Du Pont De Nemours And Company Treatment of CNS disorders with 4,5,6,7-tetrahydro-1H-imidazo (4,5-)-pyridines and analogs
CA2093125C (en) 1990-10-02 2003-12-16 Warner-Lambert Company Angiotensin ii antagonists
US5385894A (en) 1991-03-06 1995-01-31 Merck & Co., Inc. Disubstituted 6-aminoquinazolinones
US5238942A (en) 1991-05-10 1993-08-24 Merck & Co., Inc. Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists
WO1992020661A1 (en) 1991-05-22 1992-11-26 Merck & Co., Inc. N, n-diacylpiperazines
US5204354A (en) 1992-02-14 1993-04-20 Merck & Co., Inc. Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders
GB9208116D0 (en) 1992-04-13 1992-05-27 Ici Plc Therapeutic agents
AU675935B2 (en) 1992-04-13 1997-02-27 Astrazeneca Ab Angiotensin II antagonists against disorders associated withimpaired neuronal conduction velocity, especially diabetic neuropathy
US5246943A (en) 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5236934A (en) 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
US5344830A (en) 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
KR950704259A (ko) * 1992-12-11 1995-11-17 베르너 발데크 치환된 벤즈아제피논(Substituted Benzazepinone)
US5395844A (en) 1993-06-10 1995-03-07 The Du Pont Merck Pharmaceutical Company Imidazole 5-position substituted angiotensin II antagonists
US5348955A (en) 1993-06-22 1994-09-20 Merck & Co., Inc. N,N-diacylpiperazines
US5338740A (en) 1993-07-13 1994-08-16 Pfizer Inc. Angiotensin II receptor antagonists
AP9400651A0 (en) 1993-07-15 1995-12-30 Pfizer Azacyclic-heterocyclic compounds as angiotensin II receptor antagonists.
US5409926A (en) 1993-07-19 1995-04-25 Merck & Co., Inc. AT-2 antagonist inhibition of vascular restenosis
US5610165A (en) 1994-02-17 1997-03-11 Merck & Co., Inc. N-acylpiperidine tachykinin antagonists
FR2739625B1 (fr) 1995-10-09 1997-12-05 Atochem Elf Sa Copolymeres hydrosolubles associatifs triblocs
GB2323783A (en) 1997-04-02 1998-10-07 Ferring Bv Group Holdings Inhibitors of farnesyl protein transferase
WO1999007413A1 (en) 1997-08-11 1999-02-18 Algos Pharmaceutical Corporation Substance p inhibitors in combination with nmda-blockers for treating pain
US6277839B1 (en) 1998-10-07 2001-08-21 Merck Frosst Canada & Co. Biphenylene lactams as prostaglandin receptor ligands
CN1304000C (zh) * 1998-12-23 2007-03-14 诺瓦提斯公司 缬沙坦在制备用于治疗肺癌的药物中的用途
ATE339417T1 (de) * 1999-12-15 2006-10-15 Bristol Myers Squibb Co Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten
JP3901520B2 (ja) 1999-12-16 2007-04-04 ユニヴァースティ オブ サザーン カリフォルニア 粘膜組織の損傷の治療および予防法
AU6118001A (en) 2000-05-03 2001-11-12 Tularik Inc Combination therapeutic compositions and methods of use
AU2001282886A1 (en) 2000-07-13 2002-01-30 Pharmacia Corporation Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain
AU2002223802A1 (en) 2000-11-17 2002-05-27 Warner-Lambert Company Llc Treatment of sexual dysfunction with non peptide bombesin receptor antagonists
EG23054A (en) 2001-01-22 2004-02-29 Sankyo Co Pyrrole derivatives their preparation and their therapeutic uses
WO2002060439A1 (en) 2001-01-29 2002-08-08 Takeda Chemical Industries, Ltd. Analgesic and antiinflammatory drugs
AU2002245340A1 (en) 2001-01-29 2002-08-12 Cognetix, Inc. B-superfamily conotoxins
HUP0501017A3 (en) * 2001-12-14 2010-06-28 Targacept Methods and compositions for treatment of central nervous system disorders
WO2003064414A1 (en) 2002-01-29 2003-08-07 Vicore Pharma Ab. Tricyclic compounds useful as angiotensin ii agonists
TWI259079B (en) 2002-02-08 2006-08-01 Merck & Co Inc N-biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives
AU2003209851A1 (en) * 2002-03-20 2003-09-29 The University Of Queensland Method of treatment and/or prophylaxis
EP1501509A4 (en) 2002-04-30 2009-07-15 Merck & Co Inc ARYL-LINK-ARYL-SUBSTITUTED THIAZOLIDIN-DION- AND OXAZOLIDIN-DION AS SODIUM CHANNEL BLOCKER
CA2486302A1 (en) 2002-05-17 2003-11-27 Faust Pharmaceuticals Methods for the prevention and/or the treatment of neurological disorders
GB0212412D0 (en) 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
WO2003101381A2 (en) 2002-05-29 2003-12-11 Merck & Co., Inc. 1,2 diamido cycloalkyl sodium channel blockers
EP2283864A1 (en) 2002-07-16 2011-02-16 Elan Pharma International Ltd. Liquid dosage compositions fo stable nanoparticulate active agents
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
DE10300973A1 (de) * 2003-01-14 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
PA8597401A1 (es) * 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
WO2004099248A2 (en) 2003-05-05 2004-11-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor agtr2 (agtr2)
US7157584B2 (en) 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
WO2006066361A1 (en) 2004-12-24 2006-06-29 The University Of Queensland Method of treatment or prophylaxis
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin

Similar Documents

Publication Publication Date Title
JP2008531470A5 (https=)
Sasaki et al. Effective nose-to-brain drug delivery using a combination system targeting the olfactory region in monkeys
Bakhiya et al. Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux
Sethi et al. Growth of small cell lung cancer cells: stimulation by multiple neuropeptides and inhibition by broad spectrum antagonists in vitro and in vivo
US20080159980A1 (en) Combination cancer therapy with a GST-activated anticancer compound and another anticancer therapy
US20230119819A1 (en) Tripartite Modulators of Endosomal G Protein-Coupled Receptors
Cahalan et al. Sphingosine 1-phosphate receptor 1 (S1P1) upregulation and amelioration of experimental autoimmune encephalomyelitis by an S1P1 antagonist
US11154587B2 (en) Use of peptides to stimulate the immune system
JP2002509104A5 (https=)
EP3881859A1 (en) Methods and compositions for increasing neurogenesis and angiogenesis
Lue et al. The role of nitric oxide in the development of morphine tolerance in rat hippocampal slices
US10894035B2 (en) Use of indole compounds to stimulate the immune system
JP2024501800A (ja) 筋ジストロフィーを治療するためのエクソンスキッピングオリゴヌクレオチドコンジュゲートを含む組成物
CN101512343A (zh) 黑素瘤抑制性活性蛋白（mia）作为在黑素瘤治疗性反应中的早期指示物的应用
Kukreja et al. Tumor resection and antibodies to parathyroid hormone-related protein cause similar changes on bone histomorphometry in hypercalcemia of cancer
Nam et al. Ion pairs of risedronate for transdermal delivery and enhanced permeation rate on hairless mouse skin
Meini et al. Characterization of bradykinin B2 receptor antagonists in human and rat urinary bladder
CN118434424A (zh) 析出抑制剂
Frenguelli et al. Electrogenic uptake contributes a major component of the depolarizing action of l‐glutamate in rat hippocampal slices
DE10250870A1 (de) Zusammensetzung enthaltend Aktivatoren von IK-Kaliumkanälen und Calcineurin-Antagonisten und deren Verwendung
US20240325747A1 (en) Compositions and methods of a concomitant therapy of alternating electric fields and n-cadherin inhibitor
US20230142111A1 (en) Compositions and methods for the treatment of pervasive development disorders
US20160129034A1 (en) Combination of ro5503781, capecitabine and oxaliplantin for cancer therapy
Bowyer et al. Fluoro-gold and pentamidine inhibit the in vitro and in vivo release of dopamine in the striatum of rat.
ES2284548T3 (es) Procedimientos para preparar formulaciones farmaceuticas.